Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells

S Boridy¹, PU Le², K Petrecca² and D Maysinger*¹

Glioblastoma multiforme is a devastating disease of the central nervous system and, at present, no effective therapeutic interventions have been identified. Celastrol, a natural occurring triterpene, exhibits potent anti-tumor activity against gliomas in xenograft mouse models. In this study, we describe the cell death mechanism employed by celastrol and identify secondary targets for effective combination therapy against glioblastoma cell survival. In contrast to the previously proposed reactive oxygen species (ROS)-dependent mechanism, cell death in human glioblastoma cells is shown here to be mediated by alternate signal transduction pathways involving, but not fully dependent on, poly(ADP-ribose) polymerase-1 and caspase-3. Our studies indicate that celastrol promotes proteotoxic stress, supported by two feedback mechanisms: (i) impairment of protein quality control as revealed by accumulation of polyubiquitinated aggregates and the canonical autophagy substrate, p62, and (ii) the induction of heat-shock proteins, HSP72 and HSP90. The Michael adduct of celastrol and N-acetylcysteine, 6-N-acetylcycteinyldihydrocelastrol, had no effect on p62, nor on HSP72 expression, confirming a thiol-dependent mechanism. Restriction of protein folding stress with cycloheximide was protective, while combination with autophagy inhibitors did not sensitize cells to celastrol-mediated cytotoxicity. Collectively, these findings imply that celastrol targets proteostasis by disrupting sulfhydryl homeostasis, independently of ROS, in human glioblastoma cells. This study further emphasizes that targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance.

Cell Death and Disease (2014) 5, e1216; doi:10.1038/cddis.2014.182; published online 8 May 2014

Subject Category: Cancer

Glioblastoma multiforme (GBM) is the most prevalent and most aggressive malignant intracranial tumor in humans.¹ ² Despite therapeutic advances, GBM remains a fatal disease with an average survival time of 14.6 months following diagnosis.³ ⁴ Although the cause of primary glioblastomas is not well known, genetic abnormalities affecting growth factor receptor signaling are commonly observed,⁵ as is an intense resistance to apoptosis.⁶ At present, mainstay therapy consists of surgical resection and concomitant chemotherapy and radiotherapy with temozolomide (TMZ), a non-specific DNA alkylating agent.⁶ ⁷ Current clinical research focuses primarily on inhibiting epidermal growth factor receptor, protein kinase C and phosphoinositide 3-kinase (PI3K)–protein kinase B (PKB/AKT) signaling pathways. Thus far, however, molecular targeting of GBM in this regard has no demonstratable success.⁸ Celastrol, a naturally occurring quinone methide triterpene derived from the Thunder of God Vine, is a pleiotropic compound showing anti-tumor,⁹–¹² anti-inflammatory,¹³–¹⁶ anti-hypertensive,¹⁷ and anti-diabetic activity¹⁸ in numerous cellular and in vivo models. Of particular relevance to GBM treatment, celastrol inhibits the growth of human glioma xenografts in mice¹⁹ ²⁰ and was selected from a screen of over 2000 natural products for its potential to synergistically enhance the anti-cancer response to TMZ.²¹

A plethora of molecular mechanisms has been described for celastrol-mediated cell death in cancer cells. The prevailing hypotheses propose activation of apoptosis via death receptor upregulation²² ²³ and/or inhibition of NFκB-mediated pro-survival signaling.¹² ²⁴ ²⁷ Most recently, a pathway linking mitochondrial electron transport chain inhibition, leading to reactive oxygen species (ROS) generation and subsequent c-Jun N-terminal kinase (JNK) activation, has been proposed as a unifying mechanism in human non-small cell lung carcinoma²⁸ and mouse melanoma cell lines.¹¹ It is conceivable that the mechanism(s) of this pleiotropic drug encompass convergent pathways in a context- and cell-dependent manner.

¹Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, McIntyre Medical Building, Montreal, Quebec, Canada and ²Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada

Corresponding author: D Maysinger, Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, 3655 Promenade Sir William Osler, McIntyre Medical Sciences Building, Montreal, Quebec H3G1Y6, Canada. Tel: +1 514 398 1264; Fax: +1 514 398 6690; E-mail: dusica.maysinger@mcgill.ca

Keywords: celastrol; 17-AAG; autophagy; p62/SGSTM1; glioblastoma; heat-shock protein 90

Abbreviations: 17-AAG, 17-N-Allylamino-17-demethoxygeldanamycin; DTT, dithiothreitol; ER, endoplasmic reticulum; ESI-MS, electrospray ionization mass spectrometer; GBM, glioblastoma multiforme; GSH, glutathione; HSE, heat-shock response element; HSF-1, heat-shock factor 1; HSP, heat-shock protein; KEAP-1, Kelch-like-ECH-associated protein 1; L-BSO, L-buthionine sulfoximine; NAC, N-acetylcycteine; PARP-1, poly(ADP-ribose) polymerase-1; ROS, reactive oxygen species; SAPK, stress-activated protein kinase

Received 04.12.13; revised 06.3.14; accepted 24.3.14; Edited by A Finazzi-Agrò
The goals of the present study were to gain insight into the mechanism of cell death mediated by celastrol in glioblastoma cells and, ultimately, to identify a secondary target for potential drug combinations to treat GBM. The results support the concept that celastrol-induced cell death of glioblastoma is largely ROS independent, but reveal that it is mainly dependent on both the accumulation of polyubiquitinated protein aggregates and destructive autophagy, and a marked contribution of heat-shock proteins (HSPs) to cell death resistance. We propose that a synergistic cell death effect is best achieved by combining HSP90 inhibition with celastrol, and that combination therapy targeting HSPs may serve as an effective treatment for human glioblastoma.

**Results**

**Celastrol triggers human glioblastoma cell death independent of ROS-JNK signaling.** Celastrol has been proposed as a novel pharmacological intervention to inhibit the growth and invasiveness of many different cancers, particularly human gliomas.10,19,20 We investigated the molecular mechanism of celastrol-induced cell death in a well-characterized human glioblastoma cell line, U251N, derived from a malignant glioblastoma tumor explanted from a 70-year-old Caucasian male patient.29-31

Celastrol is thought to orchestrate a form of cell death that is dependent on the formation of ROS and the subsequent activation of ROS-responsive stress-activated protein kinases (SAPKs), such as JNK, to mediate a pro-apoptotic response10 (Figure 1a). In the present study, we show a significant loss of cell viability with >1 μM celastrol after 24 h of treatment in U251N (Figure 1b and Supplementary Figure S1), which was particularly marked under nutrient-rich conditions (LD50: 4.07 ± 0.29 μM (Serum - ) versus 3.16 ± 0.09 μM (Serum +); P = 2.67 × 10⁻¹²) (Figure 1c). These findings are in stark contrast to those obtained in cancerous cells (e.g., PC12) under conditions of excessive ROS production following serum deprivation.32 To determine the extent to which cellular redox status influences celastrol-mediated cytotoxicity, we manipulated the endogenous levels of glutathione (GSH), the primary cellular antioxidant. Pretreatment of human glioblastoma with 50 μM L-buthionine sulfoximine (L-BSO), an inhibitor of γ-glutamylcysteine synthetase which catalyzes the rate-limiting step in GSH synthesis, did not significantly alter the response to celastrol (LD50: 3.65 ± 0.24 μM without L-BSO versus 3.25 ± 0.27 μM with LBS; P = 1.06; Figure 1d), although GSH synthesis was sufficiently attenuated (Figure 1e). Further corroborating these results, inhibition of celastrol-mediated JNK activation with SP600125, as measured by immunoblotting for phospho-JNK (Supplementary Figure S2), had no effect on celastrol’s dose–response in glioblastoma (LD50: 2.5 ± 0.2 μM without SP versus 2.2 ± 0.58 μM with 10 μM SP and 1.89 ± 0.71 μM with 20 μM SP; P = 0.0834; Figure 1f). These results suggest an alternative mechanism of cell death mediated by the triterpenoid in glioblastoma cells.

To further our investigation, we looked at the pro-apoptotic caspase-3. Poly(ADP-ribose) polymerase-1 (PARP-1) cleavage (Figure 2a) in response to celastrol confirmed caspases-3 activation, albeit to a reduced extent relative to the prototypical ATP-competitive kinase inhibitor staurosporine (STS). Direct measurement of caspase-3 activity using an optogenetic reporter assay showed no increase in enzymatic activity in cells exposed to celastrol but significant increase after STS exposure. These data support celastrol-induced cell death in a caspase-3-independent manner. (Supplementary Figure S3A). The specific small peptide inhibitor Ac-DEVD-CMK diminished celastrol-induced cell death by <5% (3 μM), independent of peptide concentration (LD50: 1.12 ± 0.19 μM without DEVD versus 1.45 ± 0.28 μM with 20 μM DEVD and 1.35 ± 0.14 μM with 50 μM DEVD; P = 0.000113; Figure 2b). Finally, membrane permeabilization associated with necrotic forms of cell death was not observed with celastrol (Supplementary Figure S3B). These findings suggest that the ROS-JNK-caspase-3 pathway is not required for celastrol-induced glioblastoma cell death. We therefore considered the evidence from previous studies supporting the proposed ROS-dependent mechanism of action; primarily, the capacity of thiol antioxidants to abolish the activity of a quinone methide triterpenoid, like celastrol.

**Excess free thiols, but not antioxidants, delay human glioblastoma cell death induced by celastrol.** Thiol-based antioxidants, such as N-acetylcysteine (NAC), block celastrol’s activity *in vitro* and *in vivo*11,22,33 leading some to conclude that its mechanism of action is ROS dependent. However, NAC, and free thiols in general, readily modify the reactive quinone methide moiety by nucleophilic Michael addition.34 We sought to differentiate between NAC’s antioxidant capacity and its reactive thiol by pretreating cells for 24 h with NAC and removing NAC-containing media before the addition of celastrol, markedly reducing the probability of their direct interaction (Figure 3a). Although pretreatment with 2 mM NAC did not prevent cell loss induced by celastrol (LD50: 3.38 ± 0.11 μM without NAC versus 3.55 ± 0.19 μM with NAC pretreatment; P = 0.0856), co-treatment with NAC led to a remarkable delay in this regard (LD50: 12.6 ± 161 μM; P = 1.6 × 10⁻²³), suggesting that thiol reactivity is pivotal to celastrol’s mechanism of action in glioblastoma. Notably, the NAC pretreatment paradigm diminished cell loss induced by paraquat, a potent herbicide known to mediate cell death via a ROS-dependent mechanism (Figure 3b).35 In addition, the non-thiol-based antioxidant 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was incapable of delaying the response, meanwhile co-treatment with free thiols in the form of dithiothreitol (DTT) mimicked the effect of NAC co-treatment (LD50: 5.65 ± 0.08 μM without DTT versus 12.6 ± 14.1 μM with DTT; P = 5.13 × 10⁻⁵; Figure 3c). These findings indicate that NAC interacts directly with celastrol, serving as a source of free thiols and not an antioxidant under these conditions.

Our *in vitro* studies clearly show that direct interaction between NAC and celastrol is necessary to attenuate its biological activity, suggesting that an inactive end product is produced. Because of the z,μ-unsaturated carbonyl of the quinone methide, position C-6 is highly electrophilic and thus susceptible to conjugate addition by NAC to form a Michael adduct, likely 6-N-Acetylcysteinylthiodydrocelastrol (Figure 3d), based on Klaič et al.’s findings.34 To validate this assumption,
Celastrol (10 µM) was incubated with excess NAC (2 mM) in methanol for 1 h and was subsequently analyzed by electrospray ionization mass spectrometry (ESI-MS) (see Materials and Methods). ESI-MS revealed a peak at 636.2964, corresponding to the molecular weight of the Michael addition product \([C_{34}H_{47}O_7NS + Na^+]^+\), and thereby confirming
formation of the adduct (Supplementary Figure S4). This product was also observed when the same experiment was performed in deionized water or in phosphate buffer (data not shown). Collectively, these findings point to a mode of cell death that is dependent on celastrol’s thiol reactivity and not on the induction of ROS in human glioblastoma, prompting our investigation to reveal alternative mechanisms of cell death.

Celastrol promotes accumulation of polyubiquitinated protein aggregates and leads to destructive autophagy. Celastrol is proposed to be an inhibitor of proteasomal function, resulting in the accumulation of polyubiquitinated substrates.\(^{36,37}\) We therefore tested this hypothesis in human glioblastoma cells. Celastrol caused a dose-dependent increase in ubiquitin-positive protein aggregates, in a similar manner to the prototypical proteasome inhibitor MG-132, (Figure 4a). Polyubiquitinated cargo is destined for one of two selective protein quality-control pathways: proteasomal degradation or autophagy. Recent reports suggest that celastrol can initiate autophagy.\(^{38,39}\) We first sought to measure the change in levels of the lipidated form of LC3B (LC3B-II), a marker of autophagy initiation, by western blotting. Notably, within 3 h of celastrol (3 \(\mu\)M) treatment, levels of the lipidated form of LC3B (LC3B-II), a marker of autophagy initiation, became elevated (Figure 4b and Supplementary Figure S5). In parallel with the observed LC3B-II increase, there was a significant accumulation of p62, an autophagy substrate and ubiquitin receptor, which peaked within 12 h (Figure 4c and Supplementary Figure S5). This effect was sensitive to the presence of free thiols (Supplementary Figure S6). In conjunction, p62 aggregate formation can be seen upon immunolabeling \textit{in situ} (Figure 4d). Importantly, rapamycin, a well studied mTORC1 inhibitor and autophagy inducer, did not affect LC3B processing or p62 homeostasis (Figures 4b and c and Supplementary Figure S5), even in the presence of a sustained increase in lysosome content (Supplementary Figure S7). Observations with celastrol are characteristic of a blockade in autophagic flux and are comparable to the effects exerted by chloroquine (CQ), a lysosomotropic agent and inhibitor of endosomal acidification (Figure 4c, right).

In line with this notion of impeding autophagy completion, triterpenoids, such as the betulinic acid derivative, B10, reportedly destabilize lysosomes and subsequently disrupt autophagic flux-triggering cathepsin release in glioblastoma cells.\(^{40}\) To test this hypothesis for celastrol, we stained cells with the weakly basic amine dye, LysoTracker Red, which preferentially accumulates in acidic lysosomal compartments. In contrast to CQ, celastrol treatment increased lysosomal content at minimally toxic doses (<3 \(\mu\)M) (Figures 4e and f and Supplementary Figure S7). Not surprisingly, lysosomal integrity diminished with increasing toxicity (3–10 \(\mu\)M), suggesting that celastrol’s effects indirectly overburden lysosomal degradative pathways, thereby interfering with autophagy-mediated degradation. Additionally, pretreatment with leupeptin, an inhibitor of the lysosomal-specific cathepsin B, did not block celastrol’s effects (Supplementary Figure S8), arguing against a lysosomal destabilizing mechanism of necrotic cell-death. Blocking autophagic flux upstream with 5 \(\mu\)M 3-methyladenine (3MA), an inhibitor of class III phosphatidylinositol kinase or downstream with 50 \(\mu\)M CQ does not further sensitize cells to celastrol-induced toxicity (LD50: 3.66 ± 0.31 \(\mu\)M with serum deprivation versus 3.50 ± 0.30 \(\mu\)M with CQ and 3.69 ± 0.24 \(\mu\)M with 3MA; \(P = 2.728\); Figure 4g), confirming that autophagy is already compromised by celastrol. It should be noted that both of these autophagic modulators are cytotoxic to glioblastoma within the concentration range used (Supplementary Figures S9 and S10). Furthermore, cycloheximide (CHX), which arrests \textit{de novo} protein synthesis and thereby reduces

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Caspase-3 is dispensable for celastrol-mediated cell death in human glioblastoma cells. (a) U251N cells were incubated with either serum-containing (Serum +) or serum-deprived (Serum −) media or treated with 1 \(\mu\)M STS for 12 h or 3 \(\mu\)M celastrol for 24 h in serum-deprived media. Total cell lysates were collected and immunoblotted for PARP-1 cleavage, characteristic of caspase-3 activation. Actin is used as a control for protein loading. (b) U251N cells were treated with serum-deprived media with or without the caspase-3 selective inhibitor, Ac-DEVD-CMK, at the indicated concentrations for 3 h, after which celastrol was added at various concentrations (0.1–10 \(\mu\)M) for another 24 h. Cell viability was assessed by MTT assay. Caspase-3 inhibition led to a small but significant effect in shifting the dose-response to celastrol relative to treatment with celastrol alone (LD50: 1.12 ± 0.19 \(\mu\)M with DEVD versus 1.45 ± 0.28 \(\mu\)M with 20 \(\mu\)M DEVD and 1.35 ± 0.14 \(\mu\)M with 50 \(\mu\)M DEVD; \(P = 0.000113\)). Average values and S.Ds. are reported for triplicate measurements (\(N = 3\)). Results are representative of at least three independent experiments.}
\end{figure}
of DTT significantly delayed the cell death response to celastrol (LD50: 5.65 ± 0.08 µM) with (NAC Co-Treat) or without (Serum M; NAC Pre-Treat) 2 mM NAC for a subsequent 24 h. Media was replenished with celastrol at various concentrations (0.3–10 µM) with (NAC Co-Treat) or without (Serum M; NAC Pre-Treat) 2 mM NAC for a subsequent 24 h. Cell viability was assessed as in panels (b) and (c). No significant effect was seen with trolox (P = 0.0102), whereas the presence of DTT significantly delayed the response to celastrol (LD50: 5.65 ± 0.08 µM without DTT versus 12.6 ± 14.1 µM with DTT; P = 5.13 × 10^{-5}) (see Statistical analysis section in Materials and Methods). Average values and S.Ds. are reported for triplicate measurements (N = 3). Results are representative of at least three independent experiments. **P < 0.01.

(d) Chemical structure for celastrol–NAC adduct (6-N-Acetylcycteinylthiocelastrol) formed upon Michael addition of NAC to C6 electrophilic center of the celastrol quinone methide moiety.
Figure 4  Celastrol blocks protein degradation and promotes accumulation of poly-ubiquinated substrates in human glioblastoma cells. (a) U251N cells were treated with serum-containing and serum-deprived media in the presence and absence of 500 nM 17-AAG (Hsp90 inhibitor), 10 μM MG-132 (proteasome inhibitor) and various concentrations of celastrol for 24 h. Total cell lysates were collected and immunoblotted for ubiquitin. (b and c) Cells were treated with serum-containing and serum-deprived media in the presence and absence of 10 μM MG-132 and 3 μM celastrol for 3–24 h. Total cell lysates were collected and immunoblotted for LC3B, p62 and Actin. Actin is used as a control for protein loading. (d) In situ immunolabeling of p62 in U251N cells reveals accumulation of aggresomes, as indicated by white arrowheads. Cel, Celastrol 3 μM for 8 h; Rap, Rapamycin 200 nM for 24 h. Scale bar is representative for all four panels. (e) U251N cells were treated with increasing concentrations of celastrol for 24 h and analyzed for lysosomal content as described in the Materials and Methods section. Significant differences relative to untreated cells are denoted. (f) U251N cells labeled with LysoTracker Red DND-99 are depicted with cytoplasmic membrane outlines highlighted to clarify cell delineations. Scale bar in the first panel (50 μm) is representative for all the four panels shown. (g) U251N cells were treated with serum-deprived media with or without 50 μM CQ (inhibitor of lysosomal acidification) or 5 mM 3MA (inhibitor of the class III P13K, Vps34) for 1 h after which celastrol was added at various concentrations (0.5–10 μM) for another 24 h. Cell viability was assessed using the MTT assay. No significant differences were observed with CQ or 3MA relative to celastrol alone (LD50: 3.66 ± 0.31 μM with serum deprivation versus 3.50 ± 0.30 μM with CQ and 3.69 ± 0.24 μM with 3MA; P = 2.728). (h) U251N cells were treated with serum-deprived media with or without 1 μg/ml CHX, an inhibitor of protein translation, for 1 h, after which celastrol was added at various concentrations (0.3–10 μM) for another 24 h. Cell viability was assessed using the MTT assay. A significant difference in the response to celastrol was noted with CHX-treated cells relative to treatment with celastrol alone (LD50: 5.01 ± 0.24 μM without CHX versus 14.8 ± 88.3 μM with CHX; P = 4.38 × 10⁻⁵) (see Statistical analysis section in Materials and Methods). Average values and S.Ds. are reported for triplicate measurements (N = 3). Results are representative of at least three independent experiments. **P < 0.01, ***P < 0.001
Celastrol upregulates the expression of heat-shock response genes, which delay cell death in human glioblastoma cells. (a) U251N cells were treated with serum-containing or serum-deprived media in the presence and absence of 1 μg/ml CHX, an inhibitor of protein translation, for 1 h, after which celastrol was added for 3–24 h. 17-AAG significantly shifted the dose–response to celastrol treatment relative to treatment with celastrol alone (LD50: 1.03 ± 0.12 μM without 17-AAG versus 0.69 ± 0.11 μM with 17-AAG; *P = 1.23 × 10^{-6}). Average values and S.Ds. are reported for triplicate measurements (*N = 3). Results are representative of at least three independent experiments.

(Supplementary Figure S13). These findings confirm that preservation of celastrol’s thiol-reactive moiety (i.e., quinone methide) is necessary for the upregulation of HSP72 expression.

Celastrol also induced HSP90, in a similar manner to MG-132, suggesting that proteasomal inhibition is sufficient to activate the HSP response (Figure 6b and Supplementary Figure S14). This was in contrast to studies in a prostate cancer cell line, where HSP90 protein expression remained stable with celastrol treatment for up to 24 h. 17-AAG significantly shifted the dose–response to celastrol treatment relative to treatment with celastrol alone (LD50: 1.03 ± 0.12 μM without 17-AAG versus 0.69 ± 0.11 μM with 17-AAG; *P = 1.23 × 10^{-6}). Average values and S.Ds. are reported for triplicate measurements (*N = 3). Results are representative of at least three independent experiments.
The inhibition of HSP90 by celastrol has been confirmed by others using purified preparations of HSP90 and its co-chaperone Cdc37 to show disruption of the interaction.\textsuperscript{47,48} Using 17-AAG, a canonical inhibitor of HSP90,\textsuperscript{49,50} we directly compare the effects of HSP90 inhibition to celastrol, and show a remarkable difference. Primarily, 17-AAG (500 nM) blocks HSP90, as revealed by the decrease in the stability of protein kinase clients such as Akt (Supplementary Figure S16), without robust toxicity at this concentration (Supplementary Figure S15). In agreement with these findings, at celastrol’s LDS0 (3 \textmu M), Akt expression is stable, which also suggests no inhibition of HSP90 (Supplementary Figure S16). Unlike 17-AAG, celastrol directly affects proteostasis by increasing polyubiquitinated aggregates (Figures 4a, 5a and b) and p62 accumulation (Figures 4c, 5a and b). Finally, the novel synergism revealed by combining these two compounds (Figure 6c) confirms that they do not target the same pathway but rather converging pathways implicated in proteotoxic stress. As illustrated in Figure 7, these are protein degradation and protein folding. Therefore, these data suggest an alternative mode of action for celastrol-mediated cell death, apart from HSP90 inhibition, and firmly corroborate evidence by others that 17-AAG effectively sensitizes glioma cells to chemotherapeutic drugs.\textsuperscript{51,52}

**Figure 7** Celastrol causes proteotoxicity via a thiol-sensitive mechanism in human glioblastoma. Poly-ubiquitinated protein aggregates along with the autophagy substrate and stress sensor, p62, accumulate as a result of defective protein degradation quality-control mechanisms, namely autophagy and proteasomal degradation. The disruption in proteostasis is further substantiated by the activation of cytoprotective heat-shock responses (HSP72/90).

**Discussion**

In the present study, we show that celastrol drives proteotoxicity in glioblastoma cells. This was revealed both by the accumulation of polyubiquitinated protein aggregates and by the induction of cytoprotective molecular chaperones (HSPs). Autophagic flux was further impaired as revealed by loss of lysosomal integrity and the buildup of p62, a canonical autophagy receptor for protein aggregates. Importantly, cell death occurred independently of apoptosis, indicating the importance of alternate cell death pathways. Furthermore, we identify HSPs as a key resistance mechanism to cell death mediated by celastrol, thereby highlighting a secondary target in GBM and a novel drug synergism between celastrol and the geldanamycin analog, 17-AAG.

Recent studies have suggested that celastrol mediates cell death via the induction of ROS and stress-activated kinases.\textsuperscript{11,22,33} However, these studies reported marginal ROS generation by celastrol and used the thiol-containing antioxidant NAC to illustrate dependence on this mechanism, in some cases using concentrations as high as 20 mM.\textsuperscript{33} Evidence provided herein and by others\textsuperscript{34} demonstrates unequivocally that NAC mediates a nucleophilic attack on the electrophilic center of celastrol’s quinone methide moiety (Figure 3d and Supplementary Figure S4), thereby acting as a source of free thiols and not an antioxidant. To this purpose, celastrol was also reported to deplete cysteine-containing peptides, including the reduced form of the primary cellular antioxidant GSH, and induce subsequent radiosensitization in human lung cancer cell lines.\textsuperscript{53} Conversely, in human glioblastoma cells, we did not detect a change in GSH levels (normalized to cell number) in response to celastrol (Figure 1e). Moreover, depletion of GSH with the well-characterized inhibitor of \(\gamma\)-glutamylcysteine synthetase, L-BSO, did not sensitize cells to celastrol (Figure 1d). Together, these observations indicate that celastrol acts through a mechanism reliant on the preservation of its reactivity with thiols.

Sulph hydryl reactivity is sufficient to regulate cytoprotective responses, such as antioxidant and heat-shock responses.\textsuperscript{54} Zhang \textit{et al.}\textsuperscript{54} tested the hypothesis that electrophiles, like celastrol, trigger a common cysteine-reactive mechanism to induce cytoprotective signaling mechanisms: HSF-1/heat-shock response element (HSE) and the Kelch-like-ECH-associated protein 1 (KEAP-1)/NRF2/antioxidant response element pathways. Serving as a sensor in the ‘electrophile counterattack response,’ key cysteine residues of KEAP-1, like NRF2, chemically react with electrophiles, barring its inhibitory effect on NRF2.\textsuperscript{55} Zhang \textit{et al.}\textsuperscript{54} showed that various electrophiles, independent of overall chemical structure, readily induced both NRF2 and HSF-1-dependent genes. Like NRF2, HSF-1 is also activated by a wide range of electrophiles, including celastrol; this activation, however, does not require the expression of KEAP-1, suggesting that distinct electrophile sensors exist for both NRF2 and HSF-1 pathways. In fact, the yeast HSP70 chaperone Ssa1 serves as an electrophile sensor for HSF-1,\textsuperscript{43} similar to the role of KEAP-1 in NRF2-mediated antioxidant gene induction. In the yeast homolog of HSP70, Ssa1, mutations to cysteine residues (C284 and C303) were individually sufficient to render HSF-1 unresponsive both to celastrol and 4-hydroxynonenal (4-HNE), a model protein.
organic electrophile. Similarly, conserved cysteine residues (C267 and C306) in HSP72, but not HSP70, were necessary for redox sensing in response to oxidation by methylene blue.56 Nonetheless, in contrast to 4-HNE 43 celastrol was shown by us to disrupt proteostasis in human glioblastoma, in a manner which was dependent on sulfhydryl reactivity, and was associated with the induction of HSPs. These findings suggest that celastrol may function by a mechanism that is distinct from other cysteine-reactive compounds, which directly target conserved redox-sensing mechanisms.

To provide a clear picture of celastrol’s effects in human glioblastoma cells, one that unifies observations by others with the present findings, the link between autophagy, proteostasis and endoplasmic reticulum (ER) stress must be considered. Most notably, Zhu et al.57 showed previously that celastrol activates the ER-stress response in human hepatocellular carcinoma via a mechanism that is dependent on preserved elf2α-ATF4-Noxa signaling. In line with these results, celastrol induces cytoplasmic vacuolation in several human cancer cell lines in conjunction with elevated membrane-bound LC3 (LC3-II).39 This cell phenotype is characteristic of an ER-stress response termed cytoplasmic vacuolation death or paraptosis, which is dependent on LC3.39,58,59 The delay of celastrol-induced cell death with CHX treatment in glioblastoma cells (Figures 4g, 5d and e) is directly in line with delayed celastrol-induced cell death with CHX treatment in human glioblastoma cells further validate this mechanism of cell death and explain why celastrol is more effective than a selective proteasome inhibitor (i.e., MG132) in killing cancer cells.

Serving a critical role in selective degradation of ubiquitinated substrates via autophagy.60,61 p62 (also called SQSTM1) is a receptor for Ub and LC3, potentially acting as a sensor of protein stress at the crossroads of cell survival and cell death.62–65 The inhibition of autophagy leading to the accumulation of autophagy substrates and receptors may lie upstream of proteasomal dysfunction and programmed cell death in certain cases.66 Under these conditions, p62 is believed to act by sequestering and delaying the delivery of substrates destined for proteasomal degradation, an effect which can be rescued by p62 knockdown and aggravated by overexpression.66 It is hence conceivable that p62 acts at a critical junction between tumor-promoting autophagic processing and the buildup of aggregated substrates leading to cell death by paraptosis; celastrol apparently tips the balance in favor of the latter. Future studies may reveal alternate modes of glioblastoma cell death,67 by employing chemotherapeutic drug combinations to simultaneously and/or sequentially silence chaperones and disrupt autophagy.

The present results suggest a mechanism whereby celastrol triggers the accumulation of polyubiquitinated protein aggregates by disrupting sulfhydryl homeostasis and exerting widespread proteotoxicity in glioblastoma cells, as summarized in Figure 6. Combining celastrol with drugs that place additional stress on homeostatic mechanisms (i.e., inhibition of HSPs) could exacerbate the response, whereas suppressing protein misfolding stress could protect cells from celastrol-mediated toxicity. We show that celastrol-mediated cell death in glioblastoma cells occurs independently of ROS and also highlight what we regard as the misuse of thiol-containing antioxidants (e.g., NAC) as pharmacological tools to study the mechanism of action of celastrol and other electrophilic drugs. Questions still remain as to whether or not celastrol directly inhibits autophagy signaling upstream of lysosomal fusion, thereby promoting protein aggregate deposition and proteotoxic stress. This proposal does not exclude the possibility that protein aggregates accumulate in response to proteasomal inhibition and other sulfhydryl-dependent mechanisms that subsequently place an excess burden on homeostatic pathways. Both selective autophagy and proteasomal degradation are dependent on thiol-mediated protein conjugation reactions, which are proposed new targets for celastrol’s mode of action.

**Materials and Methods**

### Solutions, media, and reagents.

- 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), NAC, l-BSO, Hoechst 33342, methyl viologen dichloride hydrate (paraquat dichloride), (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (trolox), 17-AAG, MG-132, CHX, rapamycin from Stryptomyces hygroscopicus (powder form), and GSH assay kit were purchased from Sigma-Aldrich (Oakville, ON, Canada).
- Celastrol was purchased from Cayman Chemical (Ann Arbor, MI, USA).
- DQ diphosphate was purchased from TOCRIS Biosciences through Cedarlane Laboratories (Burlington, ON, Canada).
- Caspase-3 Inhibitor III (Ac-DEVD-CMK), JNK Inhibitor II (SP600125), and anti-Actin antibody, clone C4 were purchased from Millipore (Burlington, MA, USA).
- Anti-PARP antibody (1-H250) and anti-SAPK/JNK antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
- Anti-ubiquitin and anti-Hsp70/72 antibodies were purchased from Enzo Life Sciences through Cedarlane Laboratories (Burlington, ON, Canada).
- Anti-LC3B antibody and anti-Phospho-SAPK/JNK (Thr183/Tyr185) were purchased from Cell Signaling Technologies through Cedarlane Laboratories (Burlington, ON, Canada).
- Anti-p62-SQSTM1 antibody was purchased from MBL International (Des Plaines, IL, USA).
- Anti-Hsp90 antibody was purchased by Transduction Laboratories through BD Biosciences (Mississauga, ON, Canada).
- Cell culture media, penicillin-streptomycin, heat-inactivated fetal bovine serum (FBS), DTT, and LysoTracker Red DND-99 were purchased from Invitrogen (Burlington, ON, Canada).

### Cell culture and treatments.

- U251 human glioblastoma cells and U343 human astrocytoma cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Life Technologies Inc., Burlington, ON, Canada) supplemented with 10% (v/v) FBS (Gibco) and 1% (v/v) penicillin-streptomycin (Gibco). U87 cells were cultured in Minimum Essential Medium (Gibco) supplemented with 1% (v/v) FBS (Gibco) and 1% (v/v) penicillin-streptomycin (Gibco).
- Cells were seeded in Flat-bottom 96-well plates at a concentration of 3,000 cells/well and incubated for 24 h before treatment. Cells were washed with phosphate-buffered saline (PBS), centrifuged and resuspended in complete Neurocult-NS-A proliferation medium and seeded at a concentration of 200,000 cells/flask.

---

**Cell Death and Disease**

S Boridy et al
Labeling nuclei with fluorescent dye Hoechst 33342 for cell viability determinations. U251N cells were seeded at a density of 10,000 per well into 96-well cell culture plates and left to adhere for 24 h in a final volume of 0.2 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, cells were washed once with PBS and treated with fixative (4% formaldehyde) for 10 min at 37 °C. Fixative was subsequently aspirated, and cells were washed three times with PBS and stained with 10 μM Hoechst 33342 (Sigma-Aldrich) diluted in PBS for 10 min. Cells were washed once and imaged using Operetta High Content Screening System (Perkin Elmer, Woodbridge, ON, Canada) and analyzed using Harmony High Content Imaging and Analysis Software (Perkin Elmer). Data output was in text file format and graphed using the Microsoft Excel (Microsoft Canada Inc., Mississauga, ON, Canada) and Igor Pro software (Wavemetrics, Tigard, OR, USA).

Intracellular GSH content analysis. U251N cells were seeded at a density of 300,000 per well into six-well cell culture plates and left to adhere for 24 h in a final volume of 2 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, cells were trypsinized, washed and centrifuged at 700 × g. Pellets were resuspended in 5% 5-sulfosalicylic acid solution, followed by three cycles of freeze–thaw, alternating between 5 min at −80 °C and 5 min at +37 °C. Samples were centrifuged at 10,000 × g, and supernatants were analyzed for GSH content using the GSH Assay Kit (Sigma-Aldrich; Cat. C 50230), following the manufacturer’s protocol. Data were tabulated and graphed using the Microsoft Excel and Igor Pro software.

MTT assay for mitochondrial metabolic activity as a measure of cell viability. U251N, U87, and U343 cells were seeded at a density of 50,000 per well into 24-well cell culture plates and left to adhere for 24 h in a final volume of 0.5 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, media was replenished with serum-deprived media containing MTT (0.5 mg/ml). Cells were incubated at 37 °C with 5% CO2 and >95% relative humidity for 30 min, after which media was removed. DMSO was added to lyse the cells and dissolve the formazan produced. Triplicates from each well were collected into a 96-well plate (Starstedt, Montreal, QC, Canada), and the absorbance at 595 nm of each well was measured using a Benchmark microplate reader (Bio-Rad, Mississauga, ON, Canada). Results from MTT were comparable to those obtained with cell counting (Figure 1c, Serum − versus Supplementary Figure S1). Data are expressed as the percentage of change from untreated controls and were tabulated and graphed using the Microsoft Excel and Igor Pro software.

GSCs cells were plated at a density of 20,000 cells/well in a 96-well plated overnight in stem cell culture media. 17AAG, CHX, and celastrol treatment were expressed as the percentage of change from untreated controls and were tabulated with cell counting (Figure 1c, Serum − versus Supplementary Figure S1). Data are expressed as the percentage of change from untreated controls and were tabulated and graphed using the Microsoft Excel and Igor Pro software.

Confirming 6-N-Acetylcysteinyldihydrocelastrol formation (NAC addition to celastrol). A methanol solution of celastrol (10 μM) and NAC (2 mM) was allowed to react at 37 °C for 1 h and was directly injected into an ESI-MS (Exactive Orbitrap, ThermoFisher Scientific (Ottawa, ON, Canada), Department of Chemistry/McGill University). The high-resolution and high-accuracy ESI-MS results suggest the presence of 6-N-acetylcysteinyldihydroceластrol, the Michael addition product of NAC and celastrol (see Supplementary Figure S1) [C6H4H7O7NS + Na+] requires: 636.2965, Found: 636.2964]. The NAC-celastrol adduct was also observed when the same experiment was performed in deionized water or in phosphate buffer. In the latter case, extraction with ethyl acetate had to be performed before the MS analysis.

Western blotting. Cells were seeded at a density of 300,000 per well into six-well cell culture plates and left to adhere for 24 h in a final volume of 2 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, cells were trypsinized, pelleted, resuspended in lysis buffer, sonicated briefly, centrifuged, and supernatants collected. Of the total cell extracts, 15–25 μg of protein (measured by bicinchoninic acid assay) was loaded onto a 12% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. Membranes were washed with 0.1% Tween-20 + TBS and blocked with 5% milk + 0.5% Tween-20 + TBS for 1 h at room temperature (RT) and incubated with primary antibodies diluted 1:1000–2000 in blocking solution overnight at 4 °C. After five washes with 0.1% Tween-20 + TBS, the membranes were incubated with the HRP-conjugated anti-rabbit/mouse (Bio-Rad) diluted 1:3000 in 5% milk + 0.5% Tween-20 + TBS for 1 h at RT. For five washes with 0.1% Tween-20 + TBS, HRP substrate (Luminata, Millipore, Billerica, MA, USA) was used and incubated for 5 min, following which the membranes were exposed to film (Harvard, Holliston, MA, USA). Blotting with mouse anti-actin (dilution 1:1000, Millipore, Burlington, MA, USA) was used as a housekeeping protein to control for global protein expression levels. Densitometry was performed using ImageJ (NIH, Bethesda, MD, USA), and data were tabulated and graphed using the Microsoft Excel and Igor Pro software.

Immunocytochemistry for p62. Cells were seeded at a density of 15,000 onto 12 mm Bo-Si glass coverslides placed at the base of tissue culture plate wells and left to adhere for 24 h in a final volume of 0.5 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, cells were fixed in 4% paraformaldehyde for 10 min at RT, followed by washing with PBS. Permeabilization was done using 0.1% triton-X-100 at RT for 5 min, followed by washing again with PBS. Nonspecific binding sites were blocked for 60 min with 10% goat serum diluted in PBS. The samples were then incubated overnight at 4 °C with the primary antibodies (rabbit anti-p62/SQSTM1 pAb). Following the incubation, samples were washed three times in PBS and incubated for 60 min at RT with the secondary antibodies (anti-rabbit AlexaFluor 488, 1:800, Invitrogen). Following three washes in PBS, the samples were counterstained with Hoechst 33342 (10 μM, 10 min; Invitrogen), rinsed once with distilled water, and mounted onto glass slides using Aqua-Poly/Mount (Polysciences; Warrington, PA, USA). Samples were placed at 4 °C before imaging. Images were captured on a Confocor LSM 510 META mounted onto an Axiovert 200 M inverted microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada).

Lysosomal content analysis. Cells were seeded at a density of 15,000 per well into 96-well cell culture plates and left to adhere for 24 h in a final volume of 0.2 ml serum-supplemented DMEM media (10% FBS, 1% Pen-Strep). Media was replaced with serum-deprived DMEM and treated as indicated. Following treatment, media was replenished with serum-deprived DMEM and treated as indicated. Following treatment, cells were fixed in 4% paraformaldehyde for 10 min at RT, followed by washing with PBS. Permeabilization was done using 0.1% triton-X-100 at RT for 5 min, followed by washing again with PBS. Nonspecific binding sites were blocked for 60 min with 10% goat serum diluted in PBS. The samples were then incubated overnight at 4 °C with the primary antibodies (rabbit anti-p62/ SQSTM1 pAb). Following the incubation, samples were washed three times in PBS and incubated for 60 min at RT with the secondary antibodies (anti-rabbit AlexaFluor 488, 1:800, Invitrogen). Following three washes in PBS, the samples were counterstained with Hoechst 33342 (10 μM, 10 min; Invitrogen), rinsed once with distilled water, and mounted onto glass slides using Aqua-Poly/Mount (Polysciences; Warrington, PA, USA). Samples were placed at 4 °C before imaging. Images were captured on a Confocor LSM 510 META mounted onto an Axiovert 200 M inverted microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada).

Statistical analysis. All values presented in the Results section and figures were obtained from minimum triplicate analysis (real n is mentioned in each figure legend as it pertains to individual experiments) and from at least three independent experiments. All data were expressed as mean ± S.D. or S.E.M. When a significant effect was observed with one-way ANOVA, Dunnett’s test was used to compare all values to the relative control (comparisons are clearly indicated in the figure legends and Results section. Alternatively, Student’s t-test was used to analyze significant differences between the means of 2–4 groups, and Bonferroni’s correction was applied. For labeling in figures, the following premise was applied ubiquitously: *P<0.05, **P<0.01, ***P<0.001. To measure effects between celastrol dose–response groups, two-way ANOVA was applied, and the P-value for the measured between-groups effect is reported with Bonferroni’s.
correction applied (due to number of times > 10), this type of comparison was applied in the overall study. For this type of comparison only, an alpha level of 0.01 was set when determining if the null hypothesis was true or false.

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements**

The authors acknowledge: (1) Mr. Wolfgang Ernst Reintsch for assistance with Operetta High Content Screening System in the Department of Pharmacology and Therapeutics Green Chemistry and Green Chemicals Research Facility. Purchase of equipment in this facility was made possible with funding from the Canadian Foundation for Innovation (CFI) and the Ministère du Développement économique, innovation et exportation Québec (MDEIE). (2) Dr. Annie Castonguay for measurements and analysis with electrospray ionization mass spectrometer (ESI-MS), and (3) Dr. Mirela Matokanovic for insightful discussions. This work was supported by funding from the Canadian Institutes of Health Research (MOP-142626, MOP-119425). SB is supported by a Vanier Canada Graduate Scholarship through the Canadian Institutes of Health Research.

1. Louis DN, Oghahi H, Westler OD, Cavenee WK, Burger PC, Jouret A et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007; 114: 97–109.

2. Wen PY, Kesaris S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507.

3. Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca AC et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochem Biophys Acta 2012; 1826: 338–349. S.

4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. EORTC, NCIC, NCI, CNS-NET. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 187–98.

5. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 2013; 311: 139–146.

6. Easaw JC, Mason WP, Perry J, Laperriere N, Eisenstat DT, Del Maestro R et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Can J Clin Oncol 2011; 18: e12–e13.

7. Noro AO, Lee JK, Liang GJ, Drappatz J, Ligon KL, Hammond SM, Lee EO et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013; 15: 930–935.

8. Bai RY, Staedke V, Riggs GJ. Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 2011; 17: 301–312.

9. Rajendran P, Li F, Shinnagam MK, Kannayar R, Ghosh JN, Wong KF et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/UK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 2012; 5: 631–643.

10. Kannayar R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of the N-terminal kinase and suppression of PI3K/AKT signaling pathways. Apoptosis 2011; 16: 1028–1041.

11. Lee JH, Won YS, Park KH, Lee MK, Tachibana H, Yamada K et al. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation of ROS-Dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis 2012; 17: 1275–1286.

12. Tozawa K, Sagawa M, Kishi M. Quinone methide tripterine, celastrol, induces apoptosis in Xenopus laevis A6 cells. Cell Death and Disease 2013; 4: 631–643.

13. Conn CS, Qian SB. Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. J Biol Chem 2010; 285: 27364–27371.

14. Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts apoptosis into a detrimental process. Cell Death Bioenergetics 2013; 19: 1337–1346.

15. Conn CS, Qian SB. Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. J Biol Chem 2010; 285: 27364–27371.

16. Wang Y, Gibney PA, West JD, Morano KA. The yeast Hsp70 Ssa1 is a sensor for imidazole-based inhibitors and suppresses heat shock protein 82 expression in vivo. J Cell Physiol 2011; 227: 2186–2196.

17. Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts apoptosis into a detrimental process. Cell Death Bioenergetics 2013; 19: 1337–1346.

18. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ. Celastrol synergistically enhances the anti-cancer activity of TRAIL/Apo-2L. J Cell Physiol 2012; 227: 155–164.

19. Kim Y, Kang H, Jiang SW, Ko J. Celastrol inhibits breast cancer cell invasion via suppression of NF-κB-dependent matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011; 28: 175–184.

20. Lee JH, Park B, Cho Y, Koo TH, Yoon H, Jung HS, Jin HZ et al. Inhibition of NF-κB activation targeting IκB kinase by celastrol, a quinone methide tripterine. Biochem Pharmacol 2008; 72: 1311–1321.

21. Chen G, Zhang X, Zhao M, Wang Y, Cheng X, Wang D et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 2011; 11: 170.

22. Paimela T, Hyttinen JM, Viiri J, Ryhanen T, Karjalainen RO, Salminen A et al. Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. J Cell Physiol 2012; 227: 819–827.

23. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W et al. Celastrol inhibits growth and induces apoptosis of human hepatocellular carcinoma through the suppression of NF-kB-mediated matrix metalloproteinase-9 expression. J Physiol Pharmacol 2009; 60: 558–568.

24. See WY, Goh AR, Ju SM, Song HY, Kwon DJ, Jun JG et al. Celastrol induces expression of heme oxygenase-1 through ROS/NFAT2/ARE signaling in the HaCaT cells. Biochim Biophys Acta 2011; 1815: 535–540.

25. Kraic L, Trippier PC, Mishra RK, Morimoto RI, Silverman RB. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol. J Am Chem Soc 2011; 133: 19354–19367.

26. Castello PR, Drechsel DA, Patel M. Mitochondria is a major source of paracrine-induced reactive oxygen species production in the brain. J Biol Chem 2007; 282: 14185–14193.

27. Walcott SE, Heikila JA. Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp90 and hsp70, in Xenopus laevis A6 cells. Comp Biochem Physiol A Mol Integr Physiol 2010; 156: 285–293.

28. Yuan H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine”, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758–4765.

29. Deng YT, Shi J, Liu J, Gu S. Celastrol protects human neuroblastoma SH-SY5Y cells from rotenone-induced injury through induction of autophagy. Neurochem Int 2013; 63: 1–9.

30. Wang WB, Feng LX, Yue QX, Wu WY, Guan SH, Jiang BH et al. Paraproteasome accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J Cell Physiol 2012; 227: 2186–2196.

31. González P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts apoptosis into a detrimental process. Cell Death Bioenergetics 2013; 19: 1337–1346.

32. Paimela T, Hyttinen JM, Viiri J, Ryhanen T, Karjalainen RO, Salminen A et al. Celastrol regulates innate immune response via NF-κB and Hsp70 in human retinal pigment epithelial cells. Pharmacol Res Commun 2011; 43: 501–508.

33. Kagan VE, Konduru NV, Feng W, Allen BL, Corry J, Vollov V et al. Carbon nanotubes degraded by neurotoxin myeloperoxidase induce less pulmonary inflammation. Nat Nanotechnol 2010; 5: 354–359.

34. Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db Mice. PLoS One 2013; 8: e62068.

35. Ge JX, Ding Y, Wang X, Fu S, Meng F et al. Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol Res 2010; 32: 94–100.

36. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2006; 254: 101–106.
57. Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD et al. Upregulating Noxa by ER stress, compromises degradation of ubiquitin-proteasome pathway substrates. Cell Biol 2011; 21: 608–614.

58. Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 2009; 28: 2566–2568.

59. Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P, Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis 2013; 4: e457.

60. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective autophagy. Cell Death Differ 2013; 20: 21–30.